Related Experiment Videos
[Chlamydia infection and peripartum dilated cardiomyopathy in Niger]
1Université de Bretagne Occidentale, Brest et de la Biobanque de Picardie, France. Arnaud.Cenac@univ-brest.fr
Insights
Peripartum cardiomyopathy in sub-Saharan Africa may be linked to Chlamydia pneumoniae infection. This study found higher rates of Chlamydia pneumoniae antibodies in women with peripartum cardiomyopathy compared to controls.
Area of Science:
- Cardiology
- Infectious Diseases
- Obstetrics
Context:
- Peripartum cardiomyopathy is a significant cause of cardiac failure in sub-Saharan Africa, with unknown etiology.
- This condition affects women in late pregnancy or early postpartum, presenting as dilated cardiomyopathy.
Purpose:
- To investigate a potential association between peripartum cardiomyopathy and Chlamydia infections (Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydia psittaci) in Niger.
Summary:
- The study compared 50 women with peripartum cardiomyopathy to 25 controls, testing for Chlamydia antibodies using microimmunofluorescence.
- Significantly higher IgG and IgA antibody rates for Chlamydia pneumoniae were observed in patients (96% and 80%, respectively) versus controls (80% and 56%).
- No significant differences were found for Chlamydia trachomatis or Chlamydia psittaci, and no IgM antibodies were detected for Chlamydia pneumoniae.
Impact:
- This research provides the first evidence suggesting a possible role for Chlamydia pneumoniae infection in the development of peripartum cardiomyopathy.
- Findings warrant further investigation into Chlamydia pneumoniae as a potential etiological factor and may inform diagnostic and therapeutic strategies.
Abstract:
Peripartum cardiac failure due to cardiomyopathy is common in sub-saharan Africa. The etiology is unknown. This study was performed in Niger to assess a possible relationship between peripartum cardiomyopathy and Chlamydia. A total of 50 African women presenting peripartum cardiomyopathy underwent testing for infection by Chlamydia pneumoniae, Chlamydia trachomatis, and Chlamydia psittaci. The inclusion criteria were cardiac failure during the last three months of pregnancy or first 6 months postpartum with echocardiographic evidence of dilated cardiomyopathy. Similar testing was carried out in a control group of 25 African women from the same geographical location without cardiac disease. Detection of specific IgG, IgA and IgM antibodies was performed using the microimmunofluorescence technique. The cut-off values were > or = 1/32 for specific IgG antibody and > or = 1/16 for specific IgA and IgM antibody. Statistical comparison of the patient and control groups was achieved using the chi 2 test. For Chlamydia pneumoniae, 48 patients (96 p. 100) versus 20 controls (80 p. 100) controls were positive for IgG antibodies (p < 0.025) and 39 patients (80 p. 100) versus 14 controls (56 p. 100) were positive for IgA antibodies (p < 0.05). No patient or control demonstrated IgM antibodies for Chlamydia pneumoniae. For Chlamydia trachomatis and Chlamydia psittaci, differences in positive rates were not statistically significant. This is the first study demonstrating infection in patients with peripartum cardiomyopathy. The possible role of Chlamydia pneumoniae is discussed.